TABLE 6.
Baseline characteristics in patients with advanced (Rai III‐IV) and early/intermediate stage (Rai 0‐II) in the bendamustine and rituximab (BR) and ibrutinib cohorts
| Advanced stage | Early/intermediate stage | P | |||||
|---|---|---|---|---|---|---|---|
| BR n = 46 (%) | ibrutinib n = 96 (%) | P | BR n = 79 (%) | ibrutinib n = 59 (%) | |||
| Age | ≤70 years | 16 (34.8) | 27 (28.1) | 0.54 | 31 (39.2) | 22 (37.3) | 0.96 |
| >70 years | 30 (65.2) | 69 (71.9) | 48 (60.8) | 37 (67.2) | |||
| Gender | Male | 31 (67.4) | 58 (60.4) | 0.54 | 49 (62.0) | 38 (64.4) | 0.91 |
| Female | 15 (32.6) | 38 (39.6) | 30 (38.0) | 21 (35.6) | |||
| Time dx‐trx a | <36 months | 25 (54.3) | 35 (36.5) | 0.07 | 50 (63.3) | 30 (50.8) | 0.20 |
| ≥36 months | 21 (45.7) | 61 (63.5) | 29 (36.7) | 29 (49.2) | |||
| del11q | No | 26 (78.8) | 77 (88.5) | 0.29 | 55 (96.5) | 41 (83.7) | 0.06 |
| Yes | 7 (21.2) | 10 (11.5) | 2 (3.5) | 8 (16.3) | |||
a
Time dx‐trx: Interval between diagnosis and treatment.